Sahajanand Medical Technologies Limited
Information Technology • Total Issue: ₹475 Cr
Category-Wise Subscription Breakdown
Latest snapshot as of Day 3 · Overall 14.20x
Valuation Multiples & Key Ratios
Sector Valuation Anchors & Multiples
Comparing Sahajanand Medical Technologies Limited asking multiples against official 10-year historical sector norms for Information Technology.
“Valuations reflect premium expectations driven by cloud engineering and enterprise AI spending pipeline.”
Grey Market Premium (GMP) History
Real-time multi-observation premium trend line and daily price movements.
IPO Timeline & Schedule
MUFG Intime India Private Limited
About Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies develops, manufactures, and markets cardiovascular devices globally. The core business is divided into two primary segments: vascular intervention products, such as coronary stents and balloon catheters, and structural heart devices, including transcatheter aortic valves and occluders. The company generates the majority of its revenue from the sale of vascular intervention devices, with the Supraflex Cruz, a biodegradable polymer-based drug-eluting stent, acting as a major contributor to its sales. Products are distributed across India, Europe, and the rest of the world through a combination of direct, hybrid, and distributor-led models, supported by an extensive network of domestic and international distributors. Operations are backed by manufacturing facilities located in Surat, Hyderabad, and Thailand. Additionally, the business relies heavily on dedicated research and development capabilities to continually enhance existing products and introduce new cardiovascular treatments.
Key Business Strengths
- Strong portfolio of vascular and structural heart medical devices
- Extensive domestic and international distribution network
- Dedicated in-house research and development capabilities
- Multiple manufacturing facilities across India and Thailand
- Diversified revenue streams from sales in over 65 countries
Key Risks & Challenges
- High dependency on revenues from the Supraflex Cruz stent
- Stringent domestic and global regulatory compliance requirements
- Vulnerability to foreign currency exchange rate fluctuations
- Reliance on limited third-party suppliers for key raw materials
- Exposure to pricing controls and healthcare reimbursement caps
Transparency & Informational Notice
Grey Market Premium (GMP) is unofficial, unregulated market pricing gathered from market participants and brokers. It is provided for educational and observation purposes only and does not represent guaranteed listing price or investment advice.